-
Join 674 other subscribers
-
Recent Posts
- Board IPR decisions finding conception and reduction to practice before critical date affirmed
- SCOTUS concludes Amgen’s anti-PCSK9 antibody claims not enabled
- Board IPR claim construction (even with harmless error) and obviousness determination affirmed
- DC findings that Vanda’s method of treatment claims are invalid for obviousness affirmed
- IPR obviousness decision reversed as prior art not shown to be analogous to Sanofi’s claimed invention
Recent Comments
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Arbitration
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Bankruptcy
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- comprising
- Conception and Reduction to Practice
- consisting of
- Contributory Infringement
- Copyright
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Exhaustion and Repair
- Experimental Use
- Expert Testimony
- Extension (156)
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Incorporation by Reference
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Intervening Rights
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Markush
- Means-plus-function
- Medical Devices
- Method claims
- Negative Limitations
- Obviousness
- Obviousness (Secondary Considerations)
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Eligibility (101)
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Adjustment (PTA)
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Product-by-Process
- Prosecution History Estoppel
- Public Accessibility
- Public Use
- Ranges
- Reexamination
- Reissue
- Royalties
- Safe Harbor, FDA exemptions (271(e)(1))
- Section 101 (see also Patentability)
- Software
- State Sovereignty
- Summary Judgment
- Terminal Disclaimers
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unenforceability
- Unjust enrichment
- Utility
- Venue
- Wherein
- Willfullness
- Written description
Archives
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Meta
- Anticipation (35 USC 102) Appeal Article III disputes Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Damages Doctrine of equivalents Enablement Generics / ANDA Indefiniteness Inducement to Infringe Infringement Inter Parties Review (IPR) Inventorship IPR Licensing Means-plus-function Obviousness Obviousness-Teaching Away Patentability Patent Eligibility (101) Prosecution History Estoppel Reexamination Software Trademarks Uncategorized Willfullness Written description
Copyright Notice
© Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com, [2011-2017]. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com with appropriate and specific direction to the original content.
Monthly Archives: December 2016
United Construction Products, Inc. D/B/A Bison Innovative Products v. Tile Tech, Inc.
Docket No. 2016-1392 MOORE, WALLACH, STOLL December 15, 2016 Brief Summary: DC grant of default judgment and a permanent injunction to United for patent infringement and unfair competition claims affirmed. Summary: Tile Tech appealed DC grant of default judgment and … Continue reading
Posted in Injunction
Leave a comment
Medgraph, Inc. v. Medtronic, Inc.
Docket No. 2015-2019 LOURIE, PLAGER, TARANTO December 13, 2016 Brief Summary: DC dismissal of infringement claims against Medtronic affirmed because Medgraph did not prove “that some entity or group of entities performed all of the claimed steps” (Akamai V) and … Continue reading
Power Integrations, Inc. v. Fairchild Semiconductor Int., Inc. et al.
Docket No. 2015-1329, -1388 PROST, SCHALL, CHEN December 12, 2016 Brief Summary: Opinion addresses several grounds of appeal and cross-appeal in a long-running dispute (see, e.g., Power Int., FC 2015 and 2013) relating to the power supply controller chip market … Continue reading
U.S. Water Services, Inc., Roy Johnson v. Novozymes A/S et al.
Docket No. 2015-1950, -1967 WALLACH, HUGHES, STOLL December 15, 2016 Brief Summary: DC grant of SJ for invalidity (inherent anticipation) reversed; grant of SJ of no inequitable conduct affirmed. Summary: U.S. Water (USW) appealed DC grant of SJ to Novozymes … Continue reading
In Re: JobDiva, Inc.
Docket Nos. 2015-1960 PROST, DYK, STOLL December 12, 2016 Brief Summary: Board decision cancelling service marks for software vacated and remanded because it did not answer the question of whether users would perceive the web-based software as providing the service … Continue reading
Posted in Trademarks
Leave a comment
Cutsforth, Inc. v. MotivePower, Inc.
Docket Nos. 2015-1316 (IPR2013-00274) PROST, CLEVENGER, MOORE January 22, 2016 Non-precedential Brief Summary: FC panel held “that the Board’s Final Written Decision does not provide enough explanation to support its finding of obviousness.” Summary: Cutsforth appealed PTAB IPR decision finding … Continue reading
Posted in Inter Parties Review (IPR), IPR, Obviousness
Leave a comment
In re: NuVasive, Inc.
Docket No. 2015-1670 (IPR2013-00506) PROST, REYNA, HUGHES December 7, 2016 Brief Summary: PTAB IPR decision vacated and remanded as it failed to provide an adequate explanation of the motivation to combine the cited references. Summary: NuVasive appealed final written decision … Continue reading
Posted in Inter Parties Review (IPR), IPR, Obviousness
Leave a comment
Asetek Danmark A/S v. CMI USA Inc. et al.
Docket No. 2016-1026, -1183 PROST, REYNA, HUGHES December 6, 2016 Update (April 3, 2017): DC rulings on infringement (yes), invalidity (no), and damages affirmed. Remanded “insofar as the injunction reaches conduct by Cooler Master (regarding the covered products) that goes … Continue reading
Apple, Inc. et al. v. Ameranth, Inc. (CBM2014-00013) / Ameranth, Inc. v. Agilysis, Inc. et al. (CBM2014-00015, -00016)
Docket Nos. 2015-1703, -1704 REYNA, CHEN, STOLL November 29, 2016 Brief Summary: PTAB decision to institute CBM affirmed (no “technological invention” exception); conclusions of no patentability under §101 affirmed; conclusions of patentability under § 101 reversed (claims to “insignificant post-solution … Continue reading
Dr. Reddy’s Laboratories, Ltd. et al. (Petitioner) v. Monosol Rx, LLC (Patent Owner)
IPR2016-01111 (U.S. Pat. No. 8,603,514 B2) Decision Denying Institution of IPR December 5, 2016 Brief Summary: IPR petition denied because Dr. Reddy’s did not show obviousness by a preponderance of the evidence; no collateral estoppel since issues in two cases … Continue reading